OncoMatch/Clinical Trials/NCT04789681
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
Is NCT04789681 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Canakinumab for lung carcinoma.
Treatment: Canakinumab — This phase II trial studies the effects of canakinumab in preventing lung cancer in patients who have high-risk pulmonary nodules. Canakinumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving canakinumab may prevent the development of lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage I, IA1, IA2, IA3, IB, II, IIA, IIB, III, IIIA, IIIB, IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: curative intent therapy
Patients with history of stage I-III non-small cell lung cancer (NSCLC), who have completed treatment with curative intent
Cannot have received: anti-IL1beta
Has received prior therapy with an anti-IL1beta
Lab requirements
Blood counts
ANC ≥ 1500/uL; Platelets ≥ 100,000/uL; Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L (without erythropoietin dependency and without packed red blood cell transfusion within last 2 weeks)
Kidney function
Creatinine ≤ 1.5 x ULN OR measured or calculated creatinine clearance (CrCl) ≥ 30 mL/min for participant with creatinine levels > 1.5 x institutional ULN
Liver function
Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels > 1.5 x ULN; AST and ALT ≤ 2.5 x ULN
Absolute neutrophil count (ANC) ≥ 1500/uL ... Platelets ≥ 100 000/uL ... Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L ... Creatinine ≤ 1.5 x ULN OR measured or calculated creatinine clearance ... Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN ... AST and ALT ≤ 2.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04789681 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-IL1beta disqualifies patients from enrollment.
What disease stage is eligible?
Stage I or IA1 or IA2 or IA3 or IB or II or IIA or IIB or III or IIIA or IIIB or IIIC is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages